NCT03855358 - A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

December 30, 2020

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

DRUG

TQB2450 Injection and Anlotinib Hydrochioride Capsules

TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing